Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2016-07-30
• Target enrollment: 0
• Participant gender: All

Summary

Due to the HBV and HCV infection, about 55% hepatocellular carcinoma patients happened in China. Among them, only 10% patients can be diagnosed in early stage. Sorafenib increased PFS and OS in advanced hepatocellular carcinoma patients with liver function of Child-Pugh class A patients, but the result for Child-Pugh class B patients is unclear.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qingdao Central Hospital
• Treatments: Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• pathological or cytological confirmed advanced hepatocellular carcinoma

• 18 years to 80 years

• liver function Child-Pugh class B

• BCLC stage B or C

• estimated life time 2 months or longer

Exclusion Criteria:

• previous target therapy

• allergy to Sorafenib

• Uncontrolled Bleeding or diarrhea

• eligible for locoregional treatment